The office of Eli Lilly in San Diego, California, U.S., on September 17, 2020, displays the company’s logo. The company reported better-than-expected fourth-quarter revenue and adjusted earnings, driven by the successful launch of its new weight loss drug, Zepbound, and increased prices for its blockbuster diabetes drug, Mounjaro. Eli Lilly’s earnings per share were $2.49 adjusted, surpassing the expected $2.22, while its revenue of $9.35 billion exceeded the anticipated $8.93 billion. The company’s net income for the fourth quarter was $2.19 billion, or $2.42 per share, compared to $1.94 billion, or $2.14 per share, in the previous year. Excluding one-time items, Eli Lilly posted a per-share profit of $2.49 cents for the fourth quarter of 2023. The pharmaceutical giant recorded fourth-quarter revenue of $9.35 billion, marking a 28% increase from the previous year.
Source: www.cnbc.com
Date: 2024-02-06 06:56:03